On August 10, SBP GROUP rose 3.83% in regular trading, trading at HK$5.205/share, with turnover of HK$40.24 million.

On the news front, the company announced on August 7 that its subsidiary Chia Tai Tianqing's self-developed Beimosubai injection combined with chemotherapy followed by sequential Anlotinib capsule received NMPA marketing approval for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer. This marks the 12th approved indication for Anlotinib and the 6th approved indication for Beimosubai, further expanding the company's oncology franchise.

The approval comes amid a wave of pipeline catalysts for the company. On August 4, its BCL-2 inhibitor TQB3909 NDA was accepted by CDE for chronic lymphocytic leukemia. On August 3, its ADC drug TQB2102 received a third breakthrough therapy designation for HER2-low breast cancer. Additionally, on August 6, subsidiary Beijing Tide Pharmaceutical's second-generation Flurbiprofen patch was approved, targeting China's over 200 million chronic pain patients.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)